Experimental cell injection shows promise for rare brain metastases
NCT ID NCT06592092
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a new cell therapy called QH104 in just 3 patients whose solid tumors had spread to the lining of the brain (meningeal metastases) and had a specific marker called B7H3. The treatment uses specially engineered immune cells (CAR-γδ T cells) injected directly into the fluid around the brain. The goal was to see if it could shrink the cancer and how safe it was, but because the study is so small, the results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QH104 cell injection (allogeneic B7H3 CAR-γδ T cells)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat cancer that has spread to the lining of the brain.
What could go wrong
This is a very early, tiny study with only 3 patients, so results may not apply to others. Side effects like cytokine release syndrome are possible, and the treatment may not shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China